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Abstract
Background: Hypertension in pregnancy stand alone or with proteinuria is one of the leading causes of maternal
mortality and morbidity in the world. Epidemiological and clinical studies have shown that an inverse relationship
exists between calcium intake and development of hypertension in pregnancy though the effect varies based on
baseline calcium intake and pre-existing risk factors. The purpose of this review was to evaluate preventive effect of
calcium supplementation during pregnancy on gestational hypertensive disorders and related maternal and
neonatal mortality in developing countries.
Methods: A literature search was carried out on PubMed, Cochrane Library and WHO regional databases. Data
were extracted into a standardized excel sheet. Identified studies were graded based on strengths and limitations
of studies. All the included studies were from developing countries. Meta-analyses were generated where data
were available from more than one study for an outcome. Primary outcomes were maternal mortality, eclampsia,
pre-eclampsia, and severe preeclampsia. Neonatal outcomes like neonatal mortality, preterm birth, small for
gestational age and low birth weight were also evaluated. We followed standardized guidelines of Child Health
Epidemiology Reference Group (CHERG) to generate estimates of effectiveness of calcium supplementation during
pregnancy in reducing maternal and neonatal mortality in developing countries, for inclusion in the Lives Saved
Tool (LiST).
Results: Data from 10 randomized controlled trials were included in this review. Pooled analysis showed that
calcium supplementation during pregnancy was associated with a significant reduction of 45% in risk of
gestational hypertension [Relative risk (RR) 0.55; 95 % confidence interval (CI) 0.36-0.85] and 59% in the risk of pre-
eclampsia [RR 0.41; 95 % CI 0.24-0.69] in developing countries. Calcium supplementation during pregnancy was
also associated with a significant reduction in neonatal mortality [RR 0.70; 95 % CI 0.56-0.88] and risk of pre-term
birth [RR 0.88, 95 % CI 0.78-0.99]. Recommendations for LiST for reduction in maternal mortality were based on risk
reduction in gestational hypertensive related severe morbidity/mortality [RR 0.80; 95% CI 0.70-0.91] and that for
neonatal mortality were based on risk reduction in all-cause neonatal mortality [RR 0.70; 95% CI 0.56-0.88].
Conclusion: Calcium supplementation during pregnancy is associated with a reduction in risk of gestational
hypertension, pre-eclampsia neonatal mortality and pre-term birth in developing countries.
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Hypertension in pregnancy stand alone or with protei-
nuria is one of the leading causes of maternal mortality
and morbidity in the world [1]. Hypertensive disorders
are the second most common cause of maternal deaths
worldwide [2] and account for more than 40,000 mater-
nal deaths annually [3]. These disorders are also asso-
ciated with adverse perinatal outcomes such as stillbirth,
preterm and small for gestational age babies [4-6].
Epidemiological and clinical studies have shown that
an inverse relationship exists between calcium intake
and development of hypertension in pregnancy [4,7].
Many trials have been conducted to observe the protec-
tive effect of preventive calcium supplementation in
pregnant women [8]. There is substantial data that sup-
ports that calcium supplementation in pregnancy is
associated with reduction in gestational hypertensive
disorder [9,10], although the impact varies according to
the baseline calcium intake of the population and pre-
existing risk factors [8,11].
A previous review by Hofmyer et al. has shown that
calcium supplementation during pregnancy had a signif-
icant effect in reducing risk of gestational hypertension
and pre-eclampsia [10]. This effect was more prominent
in those studies where participants had low baseline cal-
cium intake compared to that of adequate calcium
intake [10]. Another review by Trumbo et al. had shown
that beneficial effects of calcium supplementation can-
not be generalized to USA population and suggested
that beneficial effects could only be shown in popula-
tions whose baseline calcium intake is inadequate [11].
The objective of this review was to evaluate the effect
of calcium supplementation during pregnancy in redu-
cing maternal hypertensive disorders and related mater-
nal and neonatal mortality and morbidity in developing
countries. This paper is a part of series of papers for
Lives Saved Tool (LiST) model. An intervention is cur-
rently included in the LiST if there is substantial evi-
dence that it decrease maternal mortality, neonatal/child
mortality and/or stillbirths [12]. This process is guided
by qualitative assessment of available evidence according
to Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) criteria [13] and quanti-
tative inputs according to Child Health Epidemiology
Reference Group (CHERG) guidelines [12]. For more
details of the review methods, the adapted GRADE
approach or the LiST model, see the methods and
results section and other articles in this supplement.
Methods
Searching
To identify studies that evaluated the effect of calcium
supplementation during pregnancy for prevention of
gestational hypertensive disorders, a comprehensive
search of PubMed, Cochrane Library and WHO regional
databases was carried out using different terms for cal-
cium and gestational hypertensive disorders. Following
search strategy was used for PubMed; (“Calcium” AND
“pregnancy”) AND (“Hypertension” OR “pre-eclampsia”
OR “blood pressure” OR “neonatal death” OR “preterm
“OR “low birth weight”). The search was limited to “ran-
domized trial” and “humans”. Studies were considered
for inclusion irrespective of language or status of publi-
cation. The date of last search was March 22, 2010.
Additional studies were obtained through hand search
of references from identified studies and previous
reviews.
Inclusion/exclusion criteria
All published randomized controlled trials (RCTs) in
which pregnant women received calcium supplementa-
tion as compared to control (placebo or no interven-
tion) were included. Observational studies were not
considered for inclusion as we expected to have rea-
sonable number of RCTs for inclusion in the review.
Trials which included participants diagnosed with
hypertension prior to pregnancy were excluded. Sup-
plementation started with calcium before 32 weeks of
pregnancy at the latest. As per objectives of LiST
model, all the included studies were from developing
countries [12]. The developing countries were defined
as countries with Gross National Income per capita
(GNI) below US$11,905, according to World Bank
[14]. High blood pressure was taken as defined by
authors mostly as diastolic blood pressure equal to or
greater than 90 mmHg, or an increase in systolic
blood pressure of 30 mmHg or more, or in diastolic
blood pressure of 15 mmHg or more from the base-
line. Pre-eclampsia was defined as high blood pressure
plus significant proteinuria (as defined by authors).
Ideally, a proteinuria of 1+ or greater by dipstick test-
ing, equal to or greater than 300 mg per 24 hours, or
equal to or greater than 500mg per liter is taken as
significant proteinuria [15]. Gestational hypertension
was defined as high blood pressure developed during
pregnancy ± proteinuria (not significant enough to
define as pre-eclampsia). Definition of severe pre-
eclampsia was also followed as defined by authors
usually as systolic blood pressure ≥ 160 and/or diasto-
lic blood pressure ≥110 or more on 2 occasions 4
hours apart plus proteinuria (3+ on urine dipstick)
[15]. Eclampsia was defined as the development of
convulsions and/or unexplained coma during preg-
nancy or postpartum in patients with signs and symp-
toms of preeclampsia after 20 weeks pre-partum and
before 48 hours postpartum [15].
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All the included trials were assessed for methodologi-
cal quality and outcomes of interest using a standar-
dized form [12]. Data were abstracted for study design,
study site, methods of sequence generation, allocation
concealment, attrition and primary outcomes of inter-
est. Individual studies were evaluated according to
CHERG adaptation of GRADE technique [12,13]. In
this method of qualitative evaluation, all RCTs received
an initial score of ‘high’ and an observational study as
‘low’. The study scores were adjusted depending on
limitations of the study design. Trials with a final
grade of ‘high’ or ‘moderate’ and ‘low grade’ were
included in the analysis with exclusion of studies with
af i n a lg r a d eo f‘very low’ [12].
Quantitative data synthesis
The primary outcomes assessed were maternal mortal-
ity, gestational hypertension (± proteinuria), pre-eclamp-
sia, severe pre-eclampsia and eclampsia. Data on
neonatal outcomes like neonatal mortality, preterm
birth, low birth weight and birth of small-for-gestational
age were also extracted. Pooled analyses were conducted
where data were available from more than one study for
an outcome. The results are presented as risk ratios
(RR) and 95% confidence intervals (CIs). The assessment
of statistical heterogeneity among trials was done by
visual inspection i.e. the overlap of the confidence inter-
vals among the studies, and by the Chi square (P-value)
of heterogeneity in the meta-analyses. A low P value
(less than 0.10) or a large chi-squared statistic relative
to its degree of freedom wasc o n s i d e r e da sp r o v i d i n g
evidence of heterogeneity. The I
2 values were also
looked into and I
2 values greater than 50% were taken
as substantial and high heterogeneity. In situations of
substantial or high heterogeneity being present, causes
were explored by sensitivity analysis and random effects
model were used. Although random model is not a sub-
stitute for a thorough investigation of heterogeneity, it
takes an ‘average’ effect from all the included studies
compared to fixed models that take the exact contribu-
tion from the individual studies [16].It is thus preferred
in case of significant heterogeneity in pooled estimate.
All analyses were conducted using software Rev Man
version 5 [17]. We did a subgroup analysis based on a
priori hypothesis that calcium supplementation during
pregnancy would be more effective in reducing hyper-
tensive disorders in pregnant women who are at
increased risk for developing gestational hypertensive
disorders. Participants were defined as being at a higher
risk of developing hypertension in pregnancy in case of
teenage pregnancy, women with previous pre-eclampsia,
and women with positive roll over test and/or positive
angiotension II sensitivity test [10]. We applied CHERG
rules to collective maternal and neonatal mortality and
morbidity outcomes related to maternal hypertensive
disorders [12]. The purpose of this exercise was to get a
point estimate for effectiveness of calcium supplementa-
tion during pregnancy in reducing maternal and neona-
tal mortality due to hypertensive disorders.
Results
Trial flow
Literature search of electronic databases, and papers
from hand searches yielded a total number of 1402 titles
after removal of duplicates (Figure 1). Initially 29 studies
were considered for inclusion in the review. Out of
these seven studies were excluded due to insufficient
data on outcomes of interest [18-24]. Three studies
were excluded due to very low grade quality [25-27]. In
two trials, calcium was supplemented as therapeutic
intervention and not as preventive [28,29]. Two studies
were excluded because calcium was supplemented in
combination, either with linoleic acid [30] or L-aspartate
[31] and it was not possible to separate out their effect
from calcium supplementation. Five studies were
excluded because they were conducted in developed
countries [32-36].Finally 10 studies that met our inclu-
sion criteria were included in the review [37-46].
Study characteristics
All the included studies were randomized controlled
trials with comparison group receiving a placebo in all
except in two studies in which participants of compari-
son group were simply observed as controls [45,46].
Table 1 presents characteristics of included studies. The
starting period of calcium supplementation in all the
included studies was before 20-32 weeks of gestation
and continued till delivery. In three of the included stu-
dies [39,40,42], the participants were defined as being at
a higher risk of developing hypertension in pregnancy
(pregnant teenage girls, women with previous pre-
eclampsia or women with positive roll over test). The
dose of calcium ranged from 0.5 g/day to 2 g/day. Five
of the included studies were from Asia [38,42,43,45,46]
and four from South America [37,39-41]. One large
multicentre trial was conducted by World Health Orga-
nization (WHO) in Argentina, Egypt, India, Peru, South
Africa and Vietnam [44].
Quantitative data synthesis
Maternal mortality
Data on cause specific maternal mortality (i.e. due to
gestational hypertensive disorders) were not available in
any of the included studies. The outcome of all-cause
maternal death was reported by only one study [44],
with 1 death occurring in the intervention group and 6
deaths in the control group (RR 0.17; 95% CI 0.03-0.76).
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‘low’ level due to very low number of events. In the
same study, a cumulative outcome for severe maternal
morbidity/mortality was also reported. It included all
the severe morbidities related to maternal hypertensive
disorders that can lead to maternal death [44]. These
morbidities include: admission to intensive or special
care unit, eclampsia, severe pre-eclampsia, placental
abruption, HELLP (hemolysis, elevated liver enzyme and
low platelet count) syndrome, renal failure and maternal
death. Maternal calcium supplementation during preg-
nancy showed a significant reduction in the intervention
compared to control (RR 0.80; 95 % CI 0.70-0.91). The
overall quality grade for this outcome was that of ‘mod-
erate’ level.
Eclampsia
One large trial [44] reported outcome on eclampsia. The
trials reported 17 cases of eclampsia in 4151 participants
Totalsearches
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Figure 1 Flow diagram for identification of studies evaluating calcium supplementation during pregnancy for prevention of maternal
hypertensive disorders.
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Page 4 of 13of calcium group and 25 cases in 4161 participants of
control group giving a relative risk of 0.68 (95 % CI
0.48-0.97). A quality grade of ‘low’ was assigned due to
low number (<50 events) of events in the intervention
and control group.
Severe pre-eclampsia
The outcome of severe pre-eclampsia was reported by
three included trials [44-46] with a 30% reduction in
calcium group compared to control, however the results
were not statistically significant [(RR 0.70; 95% CI 0.46-
1.05) (Figure 2). There were a total of 4531 participants
in calcium group and 4541 participants in control
group. There was no heterogeneity in the pooled data.
The overall quality grade for this estimate was that of
‘moderate’ level due to lack of placebo in two studies
and confidence interval including unity. We did not per-
form any subgroup analysis for this outcome due to
fewer numbers of studies reporting this outcome.
Pre-eclampsia
The impact of calcium supplementation during preg-
nancy on risk of pre-eclampsia was reported in 10 stu-
dies [37-46]. The analysis comprising 5697 women in
intervention group and 570 8w o m e ni nc o n t r o lg r o u p
showed a reduction of 59% [RR 0.41; 95 % CI 0.24-0.69,
random model] in the intervention group compared to
control (Figure 3). On visual inspection of the forest
plot, five of the included studies were showing a clear
benefit. There was a substantial heterogeneity in the
pooled data (I
2=74), so the random models were used.
The reduction was more marked in participants with a
higher pre-pregnancy risk of developing gestational
hypertensive disorders [RR 0.18, 95 % CI 0.07-0.42, ran-
d o mm o d e l ]c o m p a r e dt ot h a to fl o wr i s kw o m e n[ R R
0.51, 95 % CI 0.30-0.87]. The overall quality grade for
reduction in risk of pre-eclampsia was that of ‘High’
level.
Table 1 Characteristics of included studies
Study (ref) Country Target population Baseline
Calcium intake
as Low
(< 900 mg/day),
Adequate
(>900g/day),
Not specified)
Dose of
Supplementation
(Cumulative
dose)
Duration of
supplementation
GRADE
quality
Belizan et al
1991[37]
Argentina Nulliparous pregnant women, < 20
weeks gestation. No comorbid
Low 2 g/day < 20 weeks of
pregnancy till
delivery
High
Kumar et al
2009 [38]
India Primigravida women with gestational
age between 12-25 weeks
Low 2 g/day 12-25 weeks of
pregnancy till
delivery
High
L-Jaramillo
et al. 1989
[41]
Ecuador Nulliparous pregnant women, < 24
weeks of gestation.
No comorbid
Low 2 g/day 23 weeks of
pregnancy till
delivery
Moderate
L-Jaramillo
et al. 1990
[40]
Ecuador Nulliparous pregnant women in 28-30
weeks of gestation with positive roll
over test
Low 2 g/day 28-30 weeks of
pregnancy till
delivery
Moderate
L-Jaramillo
et al.1997
[39]
Ecuador Teenage (< 17.5 years) Nulliparous
pregnant women < 20 weeks gestation.
No comorbids or addiction
Low 2 g/day 20 weeks of
pregnancy till
delivery
High
Niromanesh
et al. 2001
[42]
Turkey 28-32 weeks pregnant women with
positive roll over test and with at least
one risk factor for pre-eclampsia. No
chronic medical condition
Not specified 2 g/day 28-32 weeks of
pregnancy till
delivery
High
Purwar et al.
1996[43]
India Nulliparous pregnant women < 20
weeks of gestation. No cormorbid
Low 2 g/day 20 weeks of
pregnancy till
delivery
High
Villar et al.
2006 [44]
Multicenter trial
(Argentina, Egypt,
India, Peru, South
Africa and Vietnam)
Primiparous women < 20 weeks of
gestation. No comorbids
Low 1.5 g/day From enrollment
till delivery
High
Taherian
et al. 2002
[46]
Iran Nulliparous pregnant women < 20
weeks of gestation. No comrbids
Low 500 mg/day From enrollment
till delivery
Moderate
Wanchu
et al. 2001
[45]
India Nulliparous pregnant women < 20
weeks of gestation. No known
comorbids
Low 2 g/day From enrollment
till delivery
Moderate
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Page 5 of 13Gestational hypertension (± proteinuria)
The effect of calcium supplementation on gestational
hypertension (± proteinuria) was assessed in six studies
from developing countries [37,40-44]. A random effect
model pooled analysis showed a significant reduction of
45 % in risk of development of gestational hypertension
in women receiving calcium supplementation (4919
women in calcium group) as compared to those
receiving control (4942 women in control group) [RR
0.55; 95 % CI 0.36-0.85] .On visual inspection of forest
plot, four of the included studies were showing a clear
benefit in favor of intervention (Figure 4). There was a
significant heterogeneity in the pooled data (I
2=82%)
and the random models were used. The overall grade
quality for this estimate was that of ‘High’ level. Women
who were at higher risk of development of hypertension
Study or Subgroup
Taherian 2002
Villar 2006
Wanchu 2001
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.98, df = 2 (P = 0.61); I² = 0%
Test for overall effect: Z = 1.74 (P = 0.08)
Events
3
35
0
38
Total
330
4151
50
4531
Events
6
47
2
55
Total
330
4161
50
4541
Weight
10.8%
84.7%
4.5%
100.0%
M-H, Fixed, 95% CI
0.50 [0.13, 1.98]
0.75 [0.48, 1.15]
0.20 [0.01, 4.06]
0.70 [0.46, 1.05]
Calcium Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 2 Effect of calcium supplementation during pregnancy on risk of development of severe pre-eclampsia in developing countries.
Study or Subgroup
2.2.1 Low risk women
L-Jaramillo 1989
Belizan 1991
Purwar 1996
Wanchu 2001
Taherian 2002
Villar 2006
Kumar 2009
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.32; Chi² = 23.81, df = 6 (P = 0.0006); I² = 75%
Test for overall effect: Z = 2.49 (P = 0.01)
2.2.2 High women risk
L-Jaramillo 1990
L-Jaramillo 1997
Niromnesh 2001
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.36, df = 2 (P = 0.83); I² = 0%
Test for overall effect: Z = 3.89 (P = 0.0001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.41; Chi² = 34.98, df = 9 (P < 0.0001); I² = 74%
Test for overall effect: Z = 3.35 (P = 0.0008)
Events
2
15
2
9
10
171
11
220
0
4
1
5
225
Total
55
579
97
50
330
4151
273
5535
22
125
15
162
5697
Events
12
23
11
6
27
186
30
295
8
21
7
36
331
Total
51
588
93
50
330
4161
251
5524
34
135
15
184
5708
Weight
7.3%
13.6%
7.2%
10.8%
13.0%
16.7%
13.4%
82.0%
2.9%
10.2%
4.9%
18.0%
100.0%
M-H, Random, 95% CI
0.15 [0.04, 0.66]
0.66 [0.35, 1.26]
0.17 [0.04, 0.77]
1.50 [0.58, 3.90]
0.37 [0.18, 0.75]
0.92 [0.75, 1.13]
0.34 [0.17, 0.66]
0.51 [0.30, 0.87]
0.09 [0.01, 1.48]
0.21 [0.07, 0.58]
0.14 [0.02, 1.02]
0.18 [0.07, 0.42]
0.41 [0.24, 0.69]
Year
1989
1991
1996
2001
2002
2006
2009
1990
1997
2001
Calcium Placebo Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Effect of calcium supplementation during pregnancy on risk of development of pre-eclampsia in developing countries.
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Page 6 of 13during pregnancy seems to have a more prominent pre-
ventive effect of calcium supplementation [RR 0.32, 95
% CI 0.06-1.63] compared to those at lower risk [RR
0.64, 95 % CI 0.39-1.05], however the results were not
statistically significant for both the subgroups (Figure 4).
Neonatal outcomes
One study reported effect of calcium supplementation
during pregnancy on neonatal mortality [44]. There was
a significant reduction of 30 % in the intervention group
compared to placebo (RR 0.70; 95 % CI 0.56-0.88). Data
on preterm births were included from five trials
[37,38,40,43,44] and the pooled analysis showed a signifi-
cant reduction of 12% (RR 0.88; 95% CI 0.78-0.99) in the
intervention group compared to control (Figure 5). The
overall grade for this estimate was that of ‘high level’.
The outcome of risk of low birth weight in newborn was
reported in three trials [37,38,44] showing no impact of
calcium supplementation compared to control (RR 0.81
95% CI 0.58-1.12) (Figure 6). Combined data from two
studies [43,44] showed a non-significant reduction in risk
of small for gestational babies (RR 0.90; 95 % 0.59-1.38)
(data not shown). The overall quality grade for both of
the above estimates was that of ‘moderate’ level.
Recommendations for LiST
We followed standardized guidelines of Child Health
Epidemiology Reference Group (CHERG) to get a point
estimate for effectiveness of calcium supplementation
during pregnancy in reducing maternal and neonatal
mortality related to gestational hypertensive disorders in
developing countries [12]. These rules were applied to
collective mortality and morbidity outcomes to get a
most appropriate estimate for inclusion in the LiST
model. The final decision about the best estimate is
based on three components 1) the volume and consis-
tency of the evidence 2) the size of risk ratio and 3) the
strength of the statistical evidence for an association
between the intervention and outcome, as reflected by
the p-value [12]. More details about application of
CHERG rules are provided in the methods paper [12].
Additional File 1 details the quality assessment of the
calcium supplementation trials on maternal and neona-
tal outcomes. Table 2 presents the application of
CHERG rules applied to collective maternal mortality
and morbidity outcomes. The data on maternal mortal-
ity was reported in only one study [44], with a total of 7
events in both arms, which could not be used due to
Study or Subgroup
2.4.1 Low risk women
Belizan 1991
Purwar 1996
Villar 2006
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.15; Chi² = 14.21, df = 2 (P = 0.0008); I² = 86%
Test for overall effect: Z = 1.77 (P = 0.08)
2.4.2 High risk women
L-Jaramillo 1990
L-Jaramillo 1997
Niromonesh 2001
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.76; Chi² = 16.97, df = 2 (P = 0.0002); I² = 88%
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.19; Chi² = 27.84, df = 5 (P < 0.0001); I² = 82%
Test for overall effect: Z = 2.72 (P = 0.007)
Events
57
8
613
678
2
3
10
15
693
Total
579
97
4151
4827
55
22
15
92
4919
Events
87
27
645
759
12
24
11
47
806
Total
588
93
4161
4842
51
34
15
100
4942
Weight
22.9%
14.8%
25.7%
63.4%
6.6%
10.0%
19.9%
36.6%
100.0%
M-H, Random, 95% CI
0.67 [0.49, 0.91]
0.28 [0.14, 0.59]
0.95 [0.86, 1.05]
0.64 [0.39, 1.05]
0.15 [0.04, 0.66]
0.19 [0.07, 0.57]
0.91 [0.57, 1.45]
0.32 [0.06, 1.63]
0.55 [0.36, 0.85]
Calcium Placebo Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Effect of calcium supplementation during pregnancy on risk of development of gestational hypertension (±proteinuria) in developing
countries.
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Page 7 of 13number of events being less than 50 (Rule 1) [12].
Therefore, severe morbidity outcomes were considered.
Considering the direction of effect, value of effect size
and statistical significance of the estimates, reduction in
severe maternal morbidity/mortality was chosen for
inclusion in the LiST (Rule 3).This combined outcome
was reported by one study and included severe gesta-
tional hypertensive related morbidities that can lead to
maternal mortality [44]. The qualitative assessment of
this estimate was that of ‘moderate’ level however down-
graded to ‘low’ to translate it to maternal mortality[47].
To estimate the effectiveness of calcium supplementa-
tion during pregnancy on neonatal outcomes, CHERG
rules were applied to the outcomes of neonatal mortal-
ity, preterm birth, and small for gestational age and low
birth weight. One study reported all-cause neonatal
mortality which showed significant reduction of 30 %
with 37 events in the intervention and 53 events in con-
trol group [44]. The overall quality grade for this esti-
mate was that of moderate level which was also
downgraded to ‘low’ for translating all-cause into cause
specific mortality. This estimate for reduction in all-
Study or Subgroup
Belizan 1991
Kumar 2009
L-Jaramillo 1990
Purwar 1996
Villar 2006
Total (95% CI)
Total events
Heterogeneity: Chi² = 6.21, df = 4 (P = 0.18); I² = 36%
Test for overall effect: Z = 2.13 (P = 0.03)
Events
33
19
0
2
398
452
Total
527
273
22
97
4038
4957
Events
37
32
4
6
436
515
Total
542
251
34
93
4042
4962
Weight
7.1%
6.5%
0.7%
1.2%
84.6%
100.0%
M-H, Fixed, 95% CI
0.92 [0.58, 1.44]
0.55 [0.32, 0.94]
0.17 [0.01, 2.99]
0.32 [0.07, 1.54]
0.91 [0.80, 1.04]
0.88 [0.78, 0.99]
Calcium Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5 Effect of calcium supplementation during pregnancy on risk of preterm birth in developing countries.
Study or Subgroup
Belizan 1991
Kumar 2009
Villar 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.05; Chi² = 5.09, df = 2 (P = 0.08); I² = 61%
Test for overall effect: Z = 1.27 (P = 0.20)
Events
31
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Total
547
273
3930
4750
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Weight
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22.1%
51.0%
100.0%
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0.77 [0.49, 1.21]
0.55 [0.32, 0.94]
0.98 [0.87, 1.10]
0.81 [0.58, 1.12]
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Figure 6 Effect of calcium supplementation during pregnancy on risk of Low Birth Weight (< 2500 g).
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LiST as effectiveness of calcium supplementation during
pregnancy for neonatal outcomes [12]. Table 3 presents
the application of CHERG rules applied to collective
neonatal mortality and morbidity outcomes.
Discussion
Role of calcium supplementation during pregnancy in
reducing hypertensive disorders has been evaluated
before. The review by Hofmeyr et al [8,10] included
studies from both developed and developing countries
and their pooled estimate had shown that calcium
supplementation during pregnancy significantly
reduced occurrence of gestational hypertension [RR
0.70, 95% CI 0.57-0.86] and pre-eclampsia [RR 0.48,
95% CI 0.33-0.69]. In the same review, risk of prema-
turity was also reduced in calcium supplemented
group compared to control however the results were
not statistically significant [RR 0.81, 95% CI 0.64-1.03].
On the other hand, a review by Trumbo and Ellwood
for US Food and Drug Administration (FDA) has
shown that the beneficial effects of calcium supple-
mentation during pregnancy cannot be generalized to
USA and populations with adequate baseline calcium
Table 2 Application of standardized rules to collective mortality and morbidity outcomes to estimate effect of calcium
supplementation during pregnancy on maternal mortality
Outcome measure Studies Total
Events
Reduction (Relative
risk)
GRADE quality of
pooled estimate
Application of standard rules
Cause specific Maternal Mortality 0 - - - -
All cause maternal mortality (n=1) 7 83%
(RR 0.17; 95% CI 0.02,
1.39)
Low Rule 1: Do not apply
< 50 events
Eclampsia (n=1) 42 32% reduction (RR
0.68; 95% CI 0.37,
1.26)
Low Rule 3: Do not apply
< 50 events
Severe gestational hypertensive
related morbidity/mortality*
(n=1) 376 20 %
(RR 0.80; 95 % CI
0.70-0.91)
Moderate
(® low)
Rule 3 applies
“If there is low- or very low-quality
evidence of effect on cause-specific
mortality,
And there is high- or moderate-quality
evidence of effect on serious morbidity…
Then use the smaller of the two effects.”
[47]
Severe
Pre-eclampsia
(n=3) 93 30%
(RR 0.70; 95% CI 0.46,
1.05)
moderate
Pre-eclampsia (n=10) 558 59 %
(RR=0.41; 95% CI 0.24-
0.69)
High
* Include any one of the following; admission to intensive or special care unit, eclampsia, severe pre-eclampsia, placental abruption, HELLP (hemolysis, elevated
liver enzyme and low platelet count) syndrome, renal failure or maternal death.
Table 3 Application of standardized rules for choice of final outcome to estimate effect of calcium supplementation
during pregnancy on neonatal mortality
Outcome
measure
Studies Total
Events
Reduction
(Relative risk)
GRADE quality of
pooled estimate
Application of standard rules
All-cause
neonatal
mortality
19 0 3 0 %
(RR 0.56-0.88)
Moderate
(® low)
Rule 1: applies
“If there is no evidence of effect on cause-specific
mortality,
And there is evidence of effect on all-cause mortality…
Then translate all-cause into cause-specific, and downgrade
the quality score by one level”[47]
Preterm Birth 5 967 12%
(RR 0.88; 95% CI
0.78, 0.99)
High
Low birth weight
(< 2500 g)
3 1159 19 %
(RR 0.81; 95 % CI
0.58-1.12]
Moderate
Small for
gestational age
28 4 1 0 %
(RR 0.90; 95 % CI
0.59-1.38)
Moderate
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luation of studies conducted in similar setting as that
of USA; however no meta-analysis was performed.
Our results are confirmatory for the above mentioned
reviews. If we pool all the studies from both developed
and developing countries, the estimates become RR 0.70
(95 % CI 0.57-0.86) for gestational hypertension, RR
0.47 (95 % CI 0.34-0.66) for pre-eclampsia and RR 0.76
(95 % CI 0.59-0.97) for risk of preterm birth. Estimates
for gestational hypertension and pre-eclampsia are simi-
lar to that of Hofmyer et al. [10] however the results for
risk of preterm birth became statistically significant.
This is due to addition of new study from India by
K u m a re ta lw h i c hh a ds h o w nas i g n i f i c a n te f f e c ti n
reduction in risk of preterm birth [38]. When we sepa-
rately pooled the results of studies from developed
countries only [32-36], the estimate came to be RR 0.77
(95% CI 0.57, 1.03, random model) for gestational
hypertension, RR 0.52 (95 % CI 0.27, 1.00, random
model) for pre-eclampsia and RR 0.63 (95 % CI 0.33,
1.19, random model) for preterm birth (data not
shown).This shows that calcium supplementation did
not have any significant effect on risk of gestational
hypertensive disorders in developed countries as is
shown in the descriptive review of FDA [11].
What could be the explanation of protective effect of
calcium supplementation during pregnancy in develop-
ing countries and no effect in developed countries?
The first and the foremost is the difference in baseline
calcium intake. In most of the included studies from
developing countries the baseline intake was low
(Table 1),while it was adequate in most of the studies
from developed countries as reported in review by
FDA [11]. Low calcium intake has been hypothesized
to cause increase in blood pressure by stimulating the
release of parathyroid hormone and/or renin which
leads to increased intracellular calcium concentration
in vascular smooth muscle cells and causes vasocon-
striction [48]. Role of calcium supplementation in
reducing hypertensive disorders in pregnancy can pos-
sibly be explained by reduction in parathyroid calcium
release and intracellular calcium concentration, thereby
reducing smooth muscle contractility and promoting
vasodilatation [49]. Calcium supplementation could
also prevent preterm labor and delivery by reducing
uterine smooth muscle contractility [36] directly and
indirectly by increasing magnesium levels [22]. The
second explanation could be prevalent malnutrition in
developing countries. It had been proposed that hor-
mones involved in blood pressure control are altered
during malnutrition and can lead to significant mor-
bidity in malnourished pregnant women [47,50].
Our review has shown that calcium supplementation
during pregnancy reduces all gestational hypertensive
related disorders. The reduction in pre-eclampsia was
more than 50% in the present review. There was a great
deal of heterogeneity in the pooled estimate which can
primarily be explained by difference in the effect size,
with significant results more strongly present in smaller
trials (Figure 3). The two major contributors to hetero-
geneity were studies by Villar et al. 2006 [44], the largest
of included studies and study by Wanchu et al. 2001
[45] the second smallest study in the pooled data.
Another explanation for this heterogeneity was the
increased effect of intervention in trials with high risk
women included, and on sub-group analysis the most
marked reduction in pre-eclampsia was in the above
group, and no heterogeneity was reported in the results
(Figure 3). The funnel plot for risk of pre-eclampsia was
not very symmetric (Figure 7). Studies with low SE con-
tributed the most to the pooled effect size however two
studies with high SE had the highest protective effect.
Publication bias may be one of the reasons of this asym-
metry of the funnel plot however this may also be due
to smaller sample size of some of the included studies.
Maternal mortality is a relatively rare event [2]. It is
very difficult to design studies powered enough to detect
a significant effect of an intervention on maternal mor-
tality. According to CHERG rules, we had recommended
r e d u c t i o ni ns e v e r em a t e r n a l morbidity/mortality as a
proxy for effectiveness of calcium supplementation dur-
ing pregnancy in reducing maternal mortality related to
gestational hypertensive disorders, for inclusion in the
LiST model. This composite outcome included gesta-
tional hypertensive related severe maternal morbidities
that can lead to maternal death [44]. This approach of
reporting potentially fatal gestational hypertensive
related maternal morbidities have also been adopted in
antioxidant trials for prevention of pre-eclampsia [51].
The overall grade evidence for this outcome was that of
‘moderate’ level which was downgraded to ‘low’ for its
recommendation as a proxy for maternal mortality. We
also applied CHERG rules to neonatal outcomes. Con-
sidering mortality and morbidity outcomes, effect size
for all-cause neonatal mortality was chosen for inclusion
in the LiST based on its statistical significance and qual-
ity grade. The overall quality grade was that of ‘moder-
ate’ level which was downgraded to ‘low’ for translating
all-cause onto cause specific mortality[47]. The benefi-
cial effect of calcium supplementation in reducing neo-
natal mortality seems to be related to reduction in
preterm birth and birth asphyxia. There was a signifi-
cant reduction of 12 % (95 % CI 1% to 22%) in preterm
birth in calcium supplemented group compared to con-
trol (Figure 5). This pathway can be related to severe
gestational hypertensive morbidities (e.g. eclampsia)
which can lead to preterm birth and birth asphyxia and
calcium supplementation has shown reduction in all
Imdad et al. BMC Public Health 2011, 11(Suppl 3):S18
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Page 10 of 13severe morbidities (Additional File 1). It is important to
note that maternal calcium supplementation during
pregnancy is not only effective in reducing neonatal
mortality but also morbidities later in childhood. A
review by Bergel and Barros had reported that offspring
of women who were supplemented with calcium during
pregnancy had low incidence of hypertension in child-
hood [52].
Our review has certain limitations. In two of the
included studies [45,46], the comparison group did not
receive the placebo but the participants were simply
observed as controls. This could have biased the
results in favor of intervention [16]. We did not look
at the side effects related to calcium supplementation
during pregnancy. The previous reviews, however, have
shown that it is not associated with any particular
harmful effects [10].
Findings of this review and those of previous reviews
gave conclusive evidence on effectiveness of calcium
supplementation during pregnancy in reducing maternal
gestational hypertensive related disorders in populations
with low baseline calcium intake [8,11]. Future research
should focus on delivery platforms, regimens and
programmatic aspect of the intervention. It would be
relevant to assess the bioavailability of calcium when
delivered for example via dietary modification or food
fortification. It is important for example to determine
effectiveness of calcium supplementation by dietary
modification at places where baseline calcium intake is
from dairy products compared with those where it is
mostly taken in from vegetarian sources. It is also
important to calculate an internationally accepted value
to define adequacy given the large variations in calcium
recommendations in different countries of the world.
Implementation of recommendation of calcium sup-
plementation to all pregnant women in developing
countries poses a major challenge to policy-makers
and program managers of these countries. It is impor-
tant to take steps for procurement of the preparation,
storage, distribution, quality-control, and compliance
assurance with daily supplements to large numbers of
pregnant women. It is also important to consider cul-
tural, financial, and educational barriers to changing
policy and lessons should be learnt from practices of
previous programs like iron+folic acid supplementation
schemes in these countries. Lack of infrastructure and
Figure 7 Funnel plot of studies evaluating effect of calcium supplementation during pregnancy in reducing risk of pre-eclampsia in developing
countries.
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Page 11 of 13poor compliance were considered as few of the major
barriers in implementation of these programs in these
countries [53]. Issues of cost effectiveness should also
be considered and weighed for increasing the calcium
intake by dietary modification or food fortification.
Increasing dietary calcium intake may seem to be an
easier intervention than calcium supplementation,
although availability of dairy products in many coun-
tries may not be sufficient to fulfill the need. Alterna-
tively, targeted food fortification with calcium may be
a feasible intervention, especially for high-risk women,
who may not be targeted for individual calcium sup-
plementation because they do not come for antenatal
care services [54].
Conclusion
Calcium supplementation during pregnancy leads to a
r e d u c t i o no f5 9%( 9 5%C I3 1%t o7 6% )i nr i s ko f
pre-eclampsia, 45 % (95 % CI 15 % to 64 %) in risk of
development of gestational hypertension and 12 % (95 %
CI 1% to 22 %) in risk of preterm birth in developing
countries. Calcium should be supplemented to all
women during pregnancy in developing countries.
Additional material
Additional File 1: Quality assessment of calcium supplementation
during pregnancy on maternal and neonatal outcomes
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